Abstract
Dupilumab, a monoclonal antibody targeting the IL-4 receptor subunit alpha, has revolutionized the treatment landscape for atopic dermatitis. This literature review delves into the intriguing relationship between atopic dermatitis and alopecia areata, exploring the dual impact of dupilumab on patients with these coexisting dermatological conditions. Our analysis of 25 relevant articles reveals a complex interplay where dupilumab can either exacerbate or ameliorate alopecia areata, depending on individual patient characteristics and pathogenic pathways. In our findings, while some patients experienced worsening of AA with dupilumab, others achieved remarkable hair regrowth, highlighting the double nature of its effects.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
